Anthony Letai

40.9k citations

175 papers · 18.2k indexed · 9 hit papers · h-index 62

Impact in

Hematology top 0.1%
- Acute Myeloid Leukemia Research
Genetics top 0.2%
- Chronic Lymphocytic Leukemia Research

Papers in

Hematology 43
- Acute Myeloid Leukemia Research 30
Genetics 29
- Chronic Lymphocytic Leukemia Research 26

Co-authors: Kristopher A. Sarosiek Rumani Singh Stanley J. Korsmeyer Joslyn K. Brunelle Victoria Del Gaizo Moore Jeremy Ryan Loren D. Walensky Michael Certo
Journals: Blood (45 papers)Cancer Research (12 papers)Cancer Cell (8 papers)Proceedings of the National Academy of Sciences (6 papers)Cell Death and Differentiation (5 papers)
Partner nations: United States United Kingdom Australia

In The Last Decade

Anthony Letai

173 papers receiving 18.0k citations

Hit Papers

9 papers align trajectories log scale

Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins 2019 · 1.5k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2019 Nature Reviews Molecular Cell Biology
2018 The Lancet Oncology
2018 Blood
2017 Nature
2009 Journal of Cell Science
2006 Cancer Cell
2005 Cancer Cell
2003 Nature
2002 Cancer Cell

Peers

Countries citing papers authored by Anthony Letai

Since Specialization

Citations

This map shows the geographic impact of Anthony Letai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anthony Letai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anthony Letai more than expected).

Fields of papers citing papers by Anthony Letai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anthony Letai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anthony Letai. The network helps show where Anthony Letai may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Anthony Letai, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Anthony Letai Line = papers co-authored together Anthony Letai links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Combining MCL-1 inhibition and CD37-directed chimeric antigen receptor T cells as an effective strategy to target T-cell lymphoma Leukemia ·Marcos Sobral, Felix Korell, Irene Scarfò, M. Raunio, Karina Harumi Inaka, Maria de Los Angeles Gasalla, Inês Mourato, Robert L.Maddex, Danilo Christiaan, Cort Stewart Thoreson, Harrison Silva, Gongwei Wu, Anthony Letai, Kimberly Stegmaier, Jens G. Lohr, David M. Weinstock, Marcela V. Maus, Birgit Knoechel	2025	1
2	Senolysis by ABT-263 is associated with inherent apoptotic dependence of cancer cells derived from the non-senescent state Cell Death and Differentiation ·Fleur Jochems, شیدا آردم, J. Macdonald, Veerle W. Daniëls, Archana Mathur, Mark C. de Gooijer, Olaf van Tellingen, Anthony Letai, René Bernards	2024	5
3	Dynamic BH3 profiling identifies pro-apoptotic drug combinations for the treatment of malignant pleural mesothelioma Nature Communications ·Virend K. Somers, Jay G. Polach, Stephan Bohl, Kin-Hoe Chow, Keith L. Ligon, Raphael Bueno, Anthony Letai	2023	11
4	Quantifying requirements for mitochondrial apoptosis in CAR T killing of cancer cells Cell Death and Disease ·Alexandra L. Pourzia, Michael Olson, Stefanie R. Bailey, Angela C. Boroughs, 邬晓爽, Jeremy Ryan, Marcela V. Maus, Anthony Letai	2023	9
5	Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression Clinical Cancer Research ·Matthew L. Hemming, Patrick Bhola, St. John Mildmay, Marianne Maltheson, 修竹濱, Leona A. Doyle, Н. П. Собенин, 宋绍霞, Kelly Klega, João Fernando Martins Palma, Brian D. Crompton, Chandrajit P. Raut, Suzanne George, Anthony Letai, George D. Demetri, Ewa Sicińska	2022	6
6	JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia Leukemia ·Pelin Kurtay, 罗淦, Pereira Camila Ferreira Goncalves, Hengjie Zheng, Tríona Ní Chonghaile, Melissa Burns, Kristen E. Stevenson, Meenakshi Devidas, Mignon L. Loh, Stephen P. Hunger, Brent L. Wood, Lewis B. Silverman, David T. Teachey, Jules P.P. Meijerink, Anthony Letai, Alejandro Gutiérrez	2022	18
7	Collateral deletion of the mitochondrial AAA+ ATPase ATAD1 sensitizes cancer cells to proteasome dysfunction eLife ·Jacob M. Winter, وائل محمد فخري بني عيسى, Corey N. Cunningham, Peter Hartono, Heather R. Keys, Jordan A. Berg, Alex J. Bott, Y.H. Ho, Jeremy Ryan, Deepika Sirohi, Sheryl R. Tripp, David Alejandro Muñoz Narvaez, Neeraj Agarwal, Anthony Letai, David M. Sabatini, Matthew L. Wohlever, Jared Rutter	2022	10
8	Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis Cell ·Rongqing Pan, Jeremy Ryan, Deng Pan, Kai W. Wucherpfennig, Anthony Letai	2022	133
9	Cell Line–Specific Network Models of ER+ Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations Cancer Research ·Jorge Gómez Tejeda Zañudo, Pingping Mao, 安良益田, Kailey J. Kowalski, Gabriela N. Johnson, Guotai Xu, José Baselga, Maurizio Scaltriti, Anthony Letai, Joan Montero, Réka Albert, Nikhil Wagle	2021	18
10	MCL1 and DEDD Promote Urothelial Carcinoma Progression Molecular Cancer Research ·Andrew L. Hong, Jennifer L. Guerriero, Mihir B. Doshi, J. Garcia, Won Jun Kim, Anna C. Schinzel, Mohsen Raeesi, Rafik Puttur, Rosalyn M. Adam, David J. Kwiatkowski, Rameen Beroukhim, Anthony Letai, Jonathan E. Rosenberg, William C. Hahn	2019	4
11	Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapy BMC Gastroenterology ·R. Taylor Ripley, Deborah R. Surman, Laurence P. Diggs, Jane B. Trepel, Min-Jung Lee, Jeremy Ryan, Jeremy L. Davis, Seth M. Steinberg, Jonathan M. Hernandez, Haipeng Bian, RATMAM POORANAMOORTHY, L.A. Mudrova, Tricia Kunst, Anthony Letai, David S. Schrump	2018	6
12	Dynamic BH3 Profiling Reveals Novel Therapeutic Strategies for the Treatment of Double-Hit Lymphoma Blood ·Jennifer L. Crombie, Laura Kristine Hickman, Kristopher A. Sarosiek, Amanda L. Christie, Cameron Fraser, Shruti Bhatt, Jing Deng, Matthew S. Davids, David M. Weinstock, Anthony Letai	2017	2
13	Overcoming mutational complexity in acute myeloid leukemia by inhibition of critical pathways Science Translational Medicine ·Yoriko Saito, Yoshiki Mochizuki, Ikuko Ogahara, Takashi Watanabe, Leah J. Hogdal, Shinsuke Takagi, Kaori Sato, Akiko Kaneko, Hiroshi Kajita, Naoyuki Uchida, Takehiro Fukami, Leonard D. Shultz, Shuichi Taniguchi, Osamu Ohara, Anthony Letai, Fumihiko Ishikawa	2017	12
14	Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis Science Translational Medicine ·David Lagares, E. Branchini, Paula Grasberger, Fei Liu, Clemens K. Probst, Rod A. Rahimi, Norihiko Sakai, Gordon Yip, Jeremy Ryan, Patrick Bhola, Joan Montero, Mohit Kapoor, Murray Baron, Xaralabos Varelas, Daniel J. Tschumperlin, Anthony Letai, Andrew M. Tager	2017	161
15	The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism Blood ·Mary Ann Anderson, Jing Deng, John F. Seymour, Constantine S. Tam, Su Young Kim, Joshua Fein, Lijian Yu, Jennifer R. Brown, David Westerman, Éric Ghigo, Ian J. Majewski, David Segal, Jérôme Bellayer, David C.S. Huang, Matthew S. Davids, Anthony Letai, Andrew W. Roberts	2016	215
16	Upregulation of MAPK/MCL-1 Maintaining Mitochondrial Oxidative Phosphorylation Confers Acquired Resistance to BCL-2 Inhibitor Venetoclax in AML Blood ·Qí Zhāng, Lina Han, Ce Shi, Rongqing Pan, Man Chun John, Jeremy Ryan, Stephen E. Kurtz, Hong Mu, Vivian Ruvolo, Helen Ma, Michael Andreeff, Yingchang Mi, Jeffrey Tyner, Joel Johansson, Anthony Letai, R. Eric Davis, Marina Konopleva	2016	5
17	Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199 Cancer Discovery ·Tríona Ní Chonghaile, Justine E. Roderick, Amy A Huang, Jeremy Ryan, Stephen E. Sallan, Lewis B. Silverman, Mignon L. Loh, Stephen P. Hunger, Brent L. Wood, Daniel J. DeAngelo, Richard M. Stone, Marian H. Harris, Alejandro Gutiérrez, Michelle A. Kelliher, Anthony Letai	2014	190
18	Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers Cancer Research ·Aaron N. Hata, Alan T. Yeo, Anthony C. Faber, Eugene Lifshits, Zhao Chen, Katherine A. Cheng, Zandra E. Walton, Kristopher A. Sarosiek, Anthony Letai, Rebecca S. Heist, Mari Mino–Kenudson, Kwok‐Kin Wong, Jeffrey A. Engelman	2014	60
19	BCL2 Suppresses PARP1 Function and Nonapoptotic Cell Death Cancer Research ·Chaitali Dutta, Tovah A. Day, Nadja Kopp, Diederik van Bodegom, Matthew S. Davids, Jeremy Ryan, Liat Bird, Naveen Kommajosyula, Oliver Weigert, Akinori Yoda, Hua Fung, Jennifer R. Brown, Geoffrey I. Shapiro, Anthony Letai, David M. Weinstock	2012	45
20	Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4 ⁺ CD8 ⁺ thymocytes Proceedings of the National Academy of Sciences ·Jeremy Ryan, Joslyn K. Brunelle, Anthony Letai	2010	109

About Anthony Letai

Anthony Letai is a scholar working on Hematology, Genetics, Oncology, Molecular Biology and Immunology, having authored 175 papers that have together received 18.2k indexed citations. Recurring topics across this work include Cell death mechanisms and regulation (61 papers), Acute Myeloid Leukemia Research (30 papers), Chronic Lymphocytic Leukemia Research (26 papers), RNA Interference and Gene Delivery (26 papers), Cancer-related Molecular Pathways (15 papers), Acute Lymphoblastic Leukemia research (15 papers), Phagocytosis and Immune Regulation (15 papers) and Protein Degradation and Inhibitors (14 papers). The work is most often cited by research in Hematology (3.7k citations), Genetics (2.1k citations), Molecular Biology (12.2k citations), Oncology (4.5k citations) and Cancer Research (2.1k citations). Anthony Letai has collaborated with scholars based in United States, United Kingdom and Australia. Frequent co-authors include Kristopher A. Sarosiek, Rumani Singh, Stanley J. Korsmeyer, Joslyn K. Brunelle, Victoria Del Gaizo Moore, Jeremy Ryan, Loren D. Walensky, Michael Certo, Solly Weiler and Michael C. Bassik. Their work appears in journals such as Blood, Cancer Research, Cancer Cell, Proceedings of the National Academy of Sciences and Cell Death and Differentiation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact